natgillin/translations-raw huggingface dataset:
A compound which is (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; or a pharmaceutically acceptable salt thereof; for use in a method of treating a disease selected from cachexia, a myeloproliferative disorder, and cancer in a patient in need thereof, in combination with an additional pharmaceutical agent. 
Farmaceutski sastav koji sadrži spoj koji je (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
The compound or salt for use according to claim 23, wherein said cancer is selected from prostate cancer, renal cancer, hepatic cancer, gastric cancer, thyroid cancer, glioblastoma, Karposi's sarcoma, Castleman's disease, melanoma, cutaneous T-cell lymphoma (CTCL), cutaneous Bell lymphoma, Sezary syndrome, mycosis fungoides, acute lymphoblastic leukemia, and colorectal cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak izabran od raka prostate, raka bubrega, raka jetre, raka želuca, raka štitne žlijezde, glioblastoma, Kaposijevog sarkoma, Castlemanove bolesti, melanoma, T-staničnog kožnog limfoma (CTCL), B-staničnog kožnog limfoma, Sezary sindroma, "mycosis fungoides" (kronični T-stanični limfom), akutne limfoblastične leukemije i kolorektalnog raka.
A method of inhibiting TTR expression in a cell in vitro, the method comprising: 
Postupak za inhibiranje TTR ekspresije u stanici, te je postupak naznačen time da sadrži:
A method for producing a fired refractory ceramic product comprising the following steps: 
Postupak za proizvodnju pečenog vatrostalnog keramičkog proizvoda, naznačen time, da obuhvaća sljedeće korake:
firing of the applied batch into a fired refractory ceramic product. 
pečenje dostavljene smjese u pečeni vatrostalni keramički proizvod.
a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer, wherein said compound, pharmaceutically acceptable salt thereof or composition and second therapeutic agent are associated with one another. 
drugi terapijski agens koristan u liječenju ili sprečavanju bolesti ili stanja odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom, pri čemu navedena tvar, njena farmaceutski prihvatljiva sol ili sastav i drugi terapijski agens nisu međusobno povezani.
is CH3; in the manufacture of a medicament for the treatment of a subject suffering from or susceptible to a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
je CH3, za uporabu u proizvodnji lijeka za liječenje subjekta koji pati od ili je podložan bolesti ili stanju odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
The distribution plate (3) according to claim 1, characterized in that, the lower plates (6) are implemented so that their upper planes (15a, 15b) are completely or partially implemented under an angle relative to the horizontal plane. 
Distribucijska ploča (3) prema zahtjevu 1., naznačena time da su donje ploče (6) izvedene tako da su njihove gornje ravnine (15a, 15b) potpuno ili djelomično izvedene pod kutom u odnosu na horizontalnu ravninu.
The distribution plate (3) according to claims 1 and 2, characterized in that, the upper plates (7) are implemented so that their upper planes (14a, 14b) are completely or partially implemented under an angle relative to the horizontal plane. 
Distribucijska ploča (3) prema zahtjevima 1. i 2., naznačena time da su gornje ploče (7) izvedene tako da su njihove gornje ravnine (14a, 14b) potpuno ili djelomično izvedene pod kutom u odnosu na horizontalnu ravninu.
The distribution plate (3) according to claims from1 to 3 characterized in that, perforations in the shape of small holes are implemented through part or the entire plates (6) and (7). 
Distribucijska ploča (3) prema zahtjevima 1. do 3., naznačena time da su perforacije u obliku malih rupa izvedene kroz dio ili cijelu ploču (6) i (7).
The distribution plate (3) according to claims from1 to 3 characterized in that, perforations in the shape of slots are implemented through part or the entire plates (6) and (7). 
Distribucijska ploča (3) prema zahtjevima 1. do 3., naznačena time da su perforacije u obliku proreza izvedene kroz dio ili cijelu ploču (6) i (7).
The distribution plate (3) according to claims from 1 to 5 characterized in that, it has openings (8) intended for spraying nozzles. 
Distribucijska ploča (3) prema zahtjevima 1. do 5., naznačena time da ima otvore (8) za mlaznice za prskanje.
The distribution plate (3) according to claims from 1 to 6 characterized in that, the upper plates (7) are implemented so that their upper planes (14a, 14b) are flat. 
Distribucijska ploča (3) prema zahtjevima 1. do 6., naznačena time da su gornje ploče (7) izvedene tako da su njihove gornje ravnine (14a, 14b) ravne.
The distribution plate (3) according to claims from 1 to 6, characterized in that, the lower plates (6) are implemented so that their upper planes (15a, 15b) are flat. 
Distribucijska ploča (3) prema zahtjevima 1. do 6., naznačena time da su donje ploče (6) izvedene tako da su njihove gornje ravnine (15a, 15b) ravne.
The distribution plate (3) according to claims from 1 to 6, characterized in that, the upper plates (7) are implemented so that their upper planes (14a, 14b) are curved. 
Distribucijska ploča (3) prema zahtjevima 1. do 6., naznačena time da su gornje ploče (7) izvedene tako da su njihove gornje ravnine (14a, 14b) zakrivljene.
The distribution plate (3) according to claims from 1 to 3, characterized in that, the lower plates (6) are implemented so that their upper planes (15a, 15b) are curved. 
Distribucijska ploča (3) prema zahtjevima 1. do 3., naznačena time da su donje ploče (6) izvedene tako da su njihove gornje ravnine (15a, 15b) zakrivljene.
The compound according to claim 1 or 2, wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochlorides, hydrobromides, sulfates, methanosulfates, nitrates, maleates, acetates, citrates, fumarates, tartrates, succinates, benzoates and salts with amino acids. 
Spoj prema zahtjevu 1 ili 2, naznačen time da je farmaceutski prihvatljiva sol odabrana iz skupine koja sadrži hidrokloride, hidrobromide, sulfate, metanosulfate, nitrate, maleate, acetate, citrate, fumarate, tartrate, sukcinate, benzoate i soli s amino kiselinama.
The pharmaceutical composition according to claim 5 or 6, wherein the compound or the pharmaceutically acceptable salt thereof are covalently linked to the pharmaceutically acceptable carrier. 
Farmaceutski pripravak prema zahtjevu 5 ili 6, naznačen time da su spoj ili njegova farmaceutski prihvatljiva sol kovalentno vezani na farmaceutski prihvatljiv nosač.
The pharmaceutical composition according to any of claims 5 to 7, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, salt solutions, alcohols, oils, gelatins, carbohydrates, fatty acid esters, hydroxymethylcellulose and polyvinyl pyrrolidone. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačen time da je farmaceutski prihvatljiv nosač odabran iz skupa koji čine voda, otopine soli, alkoholi, ulja, želatina, ugljikohidrati, esteri masnih kiselina, hidroksimetilceluloza, i polivinil pirolidon.
The pharmaceutical composition according to any of claims 5 to 8, wherein the composition comprises an auxiliary agent selected from the group consisting of lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring and/or aromatic substances. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 5 do 8, naznačen time da pripravak sadrži pomoćno sredstvo odabrano iz skupine koju čine lubrikanti, konzervansi, stabilizatori, sredstva za vlaženje, emulgatori, soli za reguliranje osmotskog tlaka, puferi, tvari za bojenje i/ili aromatske tvari.
said shielding means (6) comprise exhausting means (11) for exhausting gaseous coolant from the essentially closed space to a location remote from the work piece. 
da navedena zaštitna sredstva (6) sadrže ispušna sredstva (11) za ispuhivanje plinovitog rashladnog sredstva iz uglavnom zatvorenog prostora na mjesto koje je udaljeno od izratka.
Method according to any of claim 9 to 14 characterized in that the pressure within the essentially closed space is controlled by adjusting the flow of coolant (2) sprayed and / or by adjusting the flow of gaseous coolant withdrawn from the essentially closed space. 
Postupak prema bilo kojem zahtjevu 9 do 14 naznačen time da se tlak unutar uglavnom zatvorenog prostora kontrolira podešavanjem protoka rashladnog sredstva (2) raspršivanjem i/ili podešavanjem protoka plinovitog rashladnog sredstva koje se izvlači iz uglavnom zatvorenog prostora.
isolating said antibody or fragment thereof from the culture. 
izoliranje navedenog protutijela ili njegovog fragmenta iz kulture.
detectably labeled, wherein the detectable label is selected from the group consisting of an enzyme, a radioisotope, a fluorophore and a heavy metal; or 
vidno obilježen pri čemu je detekcijska oznaka odabrana iz skupine koja se sastoji od enzima, radioizotopa, fluorofora i teških metala ili
attached to a drug. 
pričvršćen na lijek.
A pocket spring mattress for use in a bedding or seating product, comprising a plurality of parallel strings of individually pocketed coil springs, wherein at least one, and preferably essentially all, of said individually pocketed coil springs is an individually pocketed coil spring in accordance with any one of claims 1-11. 
Madrac s ušivenim oprugama (1) za upotrebu u proizvodima za spavanje ili sjedenje, koji sadrži više paralelnih nizova (3) pojedinačno ušivenih spiralnih opruga (2), pri čemu je barem jedna, a po mogućnosti zapravo sve pojedinačno ušivene spiralne opruge sukladna bilo kojem od Zahtjeva 1-11.
and additionally, two adjacent groups -RX3 may, together with the ring atoms to which they are attached, form a C5-7carbocyclic ring or a C5-7heterocyclic ring. 
te dodatno, dvije susjedne skupine -RX3 zajedno s atomima prstena, na koje su priključeni, mogu tvoriti C5-7karbociklički prsten ili C5-7heterociklički prsten.
-RZ4 is independently selected from: and 
RZ4 je neovisno odabrana od sljedećih:
PVA-146-PVA-216. A composition comprising a compound according to any one of claims 1 to 16, and a pharmaceutically acceptable carrier, diluent, or excipient. 
Sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 16, te farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćno sredstvo.
asthma, for example, atopic asthma; allergic asthma; atopic bronchial IgE-mediated asthma; bronchial asthma; extrinsic asthma; allergen-induced asthma; allergic asthma exacerbated by respiratory virus infection; infective asthma; infective asthma caused by bacterial infection; infective asthma caused by fungal infection; infective asthma caused by protozoal infection; or infective asthma caused by viral infection; 
astma, primjerice atopijska astma; alergijska astma; atopijska bronhijalna IgE-posredovana astma; bronhijalna astma; ekstrinzična astma; astma izazvana alergenom; alergijska astma pogoršana putem respiratorne virusne infekcije; infekcijska astma; infekcijska astma uzrokovana bakterijskom infekcijom; infekcijska astma uzrokovana gljivičnom infekcijom; infekcijska astma uzrokovana protozoalnom infekcijom; ili infekcijska astma uzrokovana virusnom infekcijom;
asthma co-presented with a chronic obstructive lung disease, for example, asthma co-presented with emphysema; or asthma co-presented with chronic bronchitis; 
astma koja se pojavljuje zajedno s kroničnom opstrukcijskom plućnom bolesti, primjerice astma koja se pojavljuje s emfizemom; ili astma koja se pojavljuje s kroničnim bronhitisom;
allergic conjunctivitis, for example, IgE-mediated conjunctivitis; 
alergijski konjunktivitis, primjerice IgE-posredovani konjunktivitis;
an allergic condition which is triggered by dust mite Group 1 peptidase allergen; or canine atopy. 
alergijsko stanje koje iniciraju alergeni peptidaze grinja skupine 1; ili pseća atopija.
a combination of (a) and (b). 
bilo koju kombinaciju (a) i (b).
A composition comprising the humanized anti-a2 integrin antibody of claim 1 or 3 and a pharmaceutically acceptable carrier. 
Oblik koji sadrži humanizirano anti-a2 integrin protutijelo prema zahtjevu 1 i farmaceutski prikladan nosač.
An anti-VEGF antagonist antibody, for use in a method for treating a disease having excessive angiogenesis in a subject, by administering an anti-VEGF antagonist antibody and an anti-alpha5beta1 antagonist antibody, wherein the anti-VEGF antagonist antibody and the anti-alpha5beta1 antagonist antibody are administered in concurrent treatment cycles. 
Protutijelo antagonista anti-VEGF, naznačeno time, da se upotrebljava u postupku liječenja bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
An anti-alpha5beta1 antagonist antibody, for use in a method for treating a disease having excessive angiogenesis in a subject, by administering an anti-VEGF antagonist antibody and an anti-alpha5beta1 antagonist antibody, wherein the anti-VEGF antagonist antibody and the anti-alpha5beta1 antagonist antibody are administered in concurrent treatment cycles. 
Protutijelo antagonista anti-alfa5beta1, naznačeno time, da se upotrebljava u postupku liječenja bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
An anti-VEGF antagonist antibody and an anti-alpha5beta1 antagonist antibody, for use in a method for treating a disease having excessive angiogenesis in a subject, by administering an anti-VEGF antagonist antibody and an anti-alpha5beta1 antagonist antibody, wherein the anti-VEGF antagonist antibody and the anti-alpha5beta1 antagonist antibody are administered in concurrent treatment cycles. 
Protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1, naznačeni time, da se upotrebljavaju u postupku liječenja bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
The anti-VEGF antagonist antibody and/or anti-alpha5betal antagonist antibody for use according to any one of claims 1-3, wherein the subject is further administered a therapeutic agent selected from the group consisting of an anti-neoplastic agent, a chemotherapeutic agent, a growth inhibitory agent and a cytotoxic agent. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen/i time, da se pojednincu dodatno daje terapeutsko sredstvo odabrano iz skupine koju čine: anti-neoplastično sredstvo, kemoterapeutsko sredstvo, inhibitor rasta i citotoksično sredstvo.
The anti-VEGF antagonist antibody and/or anti-alpha5beta1 antagonist antibody for use according to any one of claims 1-4, wherein the disease is selected from the group consisting of a tumor, or an immune disease, or wherein the subject has elevated alpha5beta1 levels in a diseased tissue compared to tissue from a subject not suffering from the disease. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen/i time, da je bolest odabrana iz skupine koja se sastoji od tumora, imunološke bolesti, ili pri kojoj pojedinac ima povišene razine alfa5beta1 u oboljelom tkivu, u usporedbi s tkivom kod pojedinca koji ne pati od bolesti.
The anti-VEGF antagonist antibody and/or anti-alpha5beta1 antagonist antibody for use according to claim 7, wherein the cancer is selected from the group consisting of breast cancer, cervical cancer, colorectal cancer, lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, soft tissue cancer, and multiple myeloma. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema zahtjevu 7, naznačen/i time, da je rak odabran iz skupine koju čine: rak dojke, rak cerviksa, kolorektalni rak, rak pluća, non-Hodgkinsov limfom (NHL), rak renalnih stanica, rak prostate, rak jetre, rak glave i vrata, melanom, rak jajnika, mezoteliom, rak mekog tkiva i višestruki mijelom.
The anti-VEGF antagonist antibody and/or anti-alpha5betal antagonist antibody for use according to any one of claims 1-4, wherein the disease is selected from the group consisting of retinopathy, age-induced macular degeneration, rubeosis; psoriasis, psoriatic arthritis, an inflammatory renal disease, haemolytic uremic syndrome, diabetic nephropathy, arthritis, inflammatory bowel disease, chronic inflammation, chronic retinal detachment, chronic uveitis, chronic vitritis, corneal graft rejection, corneal neovascularization, corneal graft neovascularization, Crohn's disease, myopia, ocular neovascular disease, osteoarthritis, Paget's disease, pemphigoid, polyarteritis, post-laser radial keratotomy, retinal neovascularization, Sjogren's syndrome, ulcerative colitis, graft rejection, lung inflammation, nephrotic syndrome, edema, ascites associated with malignancies, stroke, angiofibroma and neovascular glaucoma. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen/i time, da je bolest odabrana iz skupine koju čine: retinopatija, makularna degeneracija izazvana starošću, rubeoza, psorijaza, psorijatični artritis, upalna bolest bubrega, sindrom hemolitičke uremije, dijabetička nefropatija, artritis, upalna bolest crijeva, kronično zapaljenje, kronično odvajanje bubrega, kronični uveitis, kronični vitritis, odbijanje usatka rožnice, neovaskularizacija rožnice, neovaskularizacija usatka rožnice, Chronova bolest, miopija, očna neovaskularna bolest, osteoartritis, Pagetova bolest, pemfigoid, poliarteritis, post-laserska radijalna keratotomija, retinalna neovaskularizacija, Sjorgenov sindrom, ulcerativni kolitis, odbijanje usadaka, upala pluća, nefrotički sindrom, edem, ascites povezani s malignim poremećajima, udar, angiofibrom i neovaskularni glaukom.
The anti-VEGF antagonist antibody and/or anti-alpha5beta1 antagonist antibody for use according to claim 10, wherein the cytotoxic agent is a radioactive isotope, chemotherapeutic agent or a toxin. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5beta1, za uporabu prema zahtjevu 10, naznačen/i time, da citotoksično sredstvo je radioaktivni izotop, kemoterapeutsko sredstvo ili toksin.
Use of an anti-VEGF antagonist antibody in the preparation of a medicament for treating a disease having excessive angiogenesis in a subject by administering an anti-VEGF antagonist antibody and an anti-alpha5beta1 antagonist antibody, wherein the anti-VEGF antagonist antibody and the anti-alpha5betal antagonist antibody are administered in concurrent treatment cycles. 
Uporaba protutijela antagonista anti-VEGF, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
Use of an anti-alpha5beta1 antagonist antibody in the preparation of a medicament for treating a disease having excessive angiogenesis in a subject by administering an anti-VEGF antagonist antibody and an anti-alpha5beta1 antagonist antibody, wherein the anti-VEGF antagonist antibody and the anti-alpha5beta1 antagonist antibody are administered in concurrent treatment cycles. 
Uporaba protutijela antagonista anti-alfa5beta1, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGF i protutijela antagonista anti-alfa5beta1, pri čemu se protutijelo antagonista anti-VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.